Evidence
November 11, 2022Clinical Outcomes Guidelines / Policy
According to the 2022 American Association of Clinical Endocrinology (AACE) Clinical Practice Guideline, CGM is recommended for all persons with T1D, regardless of insulin delivery system, to improve A1C levels and to reduce the risk for hypoglycemia and DKA. The updated guideline likewise recommends CGM for those with T2D who are treated with insulin therapy, or who have high risk for hypoglycemia and/or who have hypoglycemia unawareness. These recommendations are Grade A—indicating the highest strength made by the AACE—and are supported by the best evidence level available, based on data from randomized controlled trials. Managed care and payer professionals should take note of this latest guideline as part of the growing body of consensus recommendations supporting the coverage of CGM in a broader population of members with diabetes.
Blonde L, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022;28(10):923-1049.
Facilitators and Barriers to Nursing Implementation of Continuous Glucose Monitoring in Critically Ill COVID-19 Patients
November 9, 2022Clinical Outcomes Article / Publication
This feasibility study of critically ill patients with COVID19 in a single medical ICU (MICU) wearing Dexcom G6 concluded real-time continuous glucose monitoring (RT-CGM) systems can be successfully implemented in the MICU using a hybrid protocol implementation approach. Nurses indicated RT-CGM provided an overall time savings and decreased the time spent in COVID19 rooms
Faulds ER, et al. Facilitators and Barriers to Nursing Implementation of Continuous Glucose Monitoring (CGM) in Critically Ill Patients With COVID-19. Endocr Pract. 2021;27(4):354-361.
Learn MoreContinuous Glucose Monitoring–Guided Insulin Administration in Hospitalized Patients With Diabetes: A Randomized Clinical Trial
November 9, 2022Clinical Outcomes Article / Publication
This randomized control trial (RCT) of 185 general medicine and surgery patients with Type 1 and Type 2 diabetes found real-time continuous glucose monitoring (RT-CGM) safe and effective for guiding insulin therapy in hospitalized patients treated with a basal-bolus insulin regimen compared with a point-of-care (POC) group with blinded CGM and POC-guided insulin adjustments. RT- CGM resulted in a similar improvement in glycemic control and a significant reduction of recurrent hypoglycemia among patients with one or more hypoglycemic events compared with POC group.
Spanakis, EK et al. Continuous Glucose Monitoring–Guided Insulin Administration in Hospitalized Patients with Diabetes: A Randomized Clinical Trial. Diabetes Care. Diabetes Care. 2022;45(10):2369-2375.
Learn MorePractical Implementation of Remote Continuous Glucose Monitoring in Hospitalized Patients with Diabetes
November 9, 2022Clinical Outcomes Article / Publication
This publication describes a retrospective analysis of an inpatient real-time continuous glucose monitoring (RT-CGM) program at a community hospital and the accuracy of the system. Authors concluded RT-CGM for inpatient diabetes monitoring is feasible, is a reliable comparator to POC (point-of-care) testing, prevents adverse patient outcomes through safe and timely treatment decisions, and poses minimal risk when used for management decisions. A corresponding podcast is available below.
Baker M, et al. Practical Implementation of Remote Continuous Glucose Monitoring in Hospitalized Patients with Diabetes. Am J Health Syst Pharm. 2022;79(6):452-458.
Learn MoreManagement of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline
November 9, 2022Clinical Outcomes Article / Publication
A clinical practice guideline for inpatient hyperglycemia management from the Endocrine Society was published in The Journal of Clinical Endocrinology & Metabolism. The guideline focuses on hyperglycemia management in non-critically ill hospitalized patients and highlights the use of emerging diabetes technology, including real-time continuous glucose monitoring (RT-CGM), for glycemic management in the hospital. Based on available evidence, the guideline recommends use of RT-CGM with confirmatory point-of-care (POC) testing for insulin dosing decisions in adults with insulin-treated diabetes hospitalized for noncritical illness who are at high risk of hypoglycemia.
Korytkowski M, et al. Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2022;107(8):2101-2128.
Learn MoreNovember 7, 2022Clinical Outcomes Coverage and Benefit Design Article / PublicationLearn MoreNovember 4, 2022Population Health Webinar / Archive
Diana Isaacs, PharmD, and the Transformation of Diabetes through Time in Range
AMGA Member Best Practices: Driving Population Health Outcomes with Connected Continuous Glucose Monitors
November 2, 2022Clinical Outcomes CGM Best Practices / Webinar / Archive
Health Equity and Diabetes Technology: A Study of Access to Continuous Glucose Monitors by Payer and Race Executive Summary
October 27, 2022CGM Technology and Digital Health Coverage and Benefit Design Population Health Article / PublicationLearn MoreOctober 12, 2022Economic Outcomes CGM Best Practices / Interview
Expert: Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner at Henry Ford Health System (HFHS)/Health Alliance Plan (HAP)
Summary: HFHS/HAP’s experience in moving continuous glucose monitoring (CGM) from the durable medical equipment (DME) benefit to pharmacy coverage, demonstrating substantial cost savings at the plan level.
Short on time? Click here for an abbreviated version of this video interview.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
According to the 2022 American Association of Clinical Endocrinology (AACE) Clinical Practice Guideline, CGM is recommended for all persons with T1D, regardless of insulin delivery system, to improve A1C levels and to reduce the risk for hypoglycemia and DKA. The updated guideline likewise recommends CGM for those with T2D who are treated with insulin therapy, or who have high risk for hypoglycemia and/or who have hypoglycemia unawareness. These recommendations are Grade A—indicating the highest strength made by the AACE—and are supported by the best evidence level available, based on data from randomized controlled trials. Managed care and payer professionals should take note of this latest guideline as part of the growing body of consensus recommendations supporting the coverage of CGM in a broader population of members with diabetes.
Blonde L, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022;28(10):923-1049.
Facilitators and Barriers to Nursing Implementation of Continuous Glucose Monitoring in Critically Ill COVID-19 Patients
November 9, 2022Clinical Outcomes Article / Publication
This feasibility study of critically ill patients with COVID19 in a single medical ICU (MICU) wearing Dexcom G6 concluded real-time continuous glucose monitoring (RT-CGM) systems can be successfully implemented in the MICU using a hybrid protocol implementation approach. Nurses indicated RT-CGM provided an overall time savings and decreased the time spent in COVID19 rooms
Faulds ER, et al. Facilitators and Barriers to Nursing Implementation of Continuous Glucose Monitoring (CGM) in Critically Ill Patients With COVID-19. Endocr Pract. 2021;27(4):354-361.
Learn MoreContinuous Glucose Monitoring–Guided Insulin Administration in Hospitalized Patients With Diabetes: A Randomized Clinical Trial
November 9, 2022Clinical Outcomes Article / Publication
This randomized control trial (RCT) of 185 general medicine and surgery patients with Type 1 and Type 2 diabetes found real-time continuous glucose monitoring (RT-CGM) safe and effective for guiding insulin therapy in hospitalized patients treated with a basal-bolus insulin regimen compared with a point-of-care (POC) group with blinded CGM and POC-guided insulin adjustments. RT- CGM resulted in a similar improvement in glycemic control and a significant reduction of recurrent hypoglycemia among patients with one or more hypoglycemic events compared with POC group.
Spanakis, EK et al. Continuous Glucose Monitoring–Guided Insulin Administration in Hospitalized Patients with Diabetes: A Randomized Clinical Trial. Diabetes Care. Diabetes Care. 2022;45(10):2369-2375.
Learn MorePractical Implementation of Remote Continuous Glucose Monitoring in Hospitalized Patients with Diabetes
November 9, 2022Clinical Outcomes Article / Publication
This publication describes a retrospective analysis of an inpatient real-time continuous glucose monitoring (RT-CGM) program at a community hospital and the accuracy of the system. Authors concluded RT-CGM for inpatient diabetes monitoring is feasible, is a reliable comparator to POC (point-of-care) testing, prevents adverse patient outcomes through safe and timely treatment decisions, and poses minimal risk when used for management decisions. A corresponding podcast is available below.
Baker M, et al. Practical Implementation of Remote Continuous Glucose Monitoring in Hospitalized Patients with Diabetes. Am J Health Syst Pharm. 2022;79(6):452-458.
Learn MoreManagement of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline
November 9, 2022Clinical Outcomes Article / Publication
A clinical practice guideline for inpatient hyperglycemia management from the Endocrine Society was published in The Journal of Clinical Endocrinology & Metabolism. The guideline focuses on hyperglycemia management in non-critically ill hospitalized patients and highlights the use of emerging diabetes technology, including real-time continuous glucose monitoring (RT-CGM), for glycemic management in the hospital. Based on available evidence, the guideline recommends use of RT-CGM with confirmatory point-of-care (POC) testing for insulin dosing decisions in adults with insulin-treated diabetes hospitalized for noncritical illness who are at high risk of hypoglycemia.
Korytkowski M, et al. Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2022;107(8):2101-2128.
Learn MoreNovember 7, 2022Clinical Outcomes Coverage and Benefit Design Article / PublicationLearn MoreNovember 4, 2022Population Health Webinar / Archive
Diana Isaacs, PharmD, and the Transformation of Diabetes through Time in Range
LEARN MOREAMGA Member Best Practices: Driving Population Health Outcomes with Connected Continuous Glucose Monitors
November 2, 2022Clinical Outcomes CGM Best Practices / Webinar / Archive
Health Equity and Diabetes Technology: A Study of Access to Continuous Glucose Monitors by Payer and Race Executive Summary
October 27, 2022CGM Technology and Digital Health Coverage and Benefit Design Population Health Article / PublicationLearn MoreOctober 12, 2022Economic Outcomes CGM Best Practices / Interview
Expert: Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner at Henry Ford Health System (HFHS)/Health Alliance Plan (HAP)
Summary: HFHS/HAP’s experience in moving continuous glucose monitoring (CGM) from the durable medical equipment (DME) benefit to pharmacy coverage, demonstrating substantial cost savings at the plan level.
Short on time? Click here for an abbreviated version of this video interview.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Facilitators and Barriers to Nursing Implementation of Continuous Glucose Monitoring in Critically Ill COVID-19 Patients
This feasibility study of critically ill patients with COVID19 in a single medical ICU (MICU) wearing Dexcom G6 concluded real-time continuous glucose monitoring (RT-CGM) systems can be successfully implemented in the MICU using a hybrid protocol implementation approach. Nurses indicated RT-CGM provided an overall time savings and decreased the time spent in COVID19 rooms
Faulds ER, et al. Facilitators and Barriers to Nursing Implementation of Continuous Glucose Monitoring (CGM) in Critically Ill Patients With COVID-19. Endocr Pract. 2021;27(4):354-361.
Learn MoreContinuous Glucose Monitoring–Guided Insulin Administration in Hospitalized Patients With Diabetes: A Randomized Clinical Trial
November 9, 2022Clinical Outcomes Article / Publication
This randomized control trial (RCT) of 185 general medicine and surgery patients with Type 1 and Type 2 diabetes found real-time continuous glucose monitoring (RT-CGM) safe and effective for guiding insulin therapy in hospitalized patients treated with a basal-bolus insulin regimen compared with a point-of-care (POC) group with blinded CGM and POC-guided insulin adjustments. RT- CGM resulted in a similar improvement in glycemic control and a significant reduction of recurrent hypoglycemia among patients with one or more hypoglycemic events compared with POC group.
Spanakis, EK et al. Continuous Glucose Monitoring–Guided Insulin Administration in Hospitalized Patients with Diabetes: A Randomized Clinical Trial. Diabetes Care. Diabetes Care. 2022;45(10):2369-2375.
Learn MorePractical Implementation of Remote Continuous Glucose Monitoring in Hospitalized Patients with Diabetes
November 9, 2022Clinical Outcomes Article / Publication
This publication describes a retrospective analysis of an inpatient real-time continuous glucose monitoring (RT-CGM) program at a community hospital and the accuracy of the system. Authors concluded RT-CGM for inpatient diabetes monitoring is feasible, is a reliable comparator to POC (point-of-care) testing, prevents adverse patient outcomes through safe and timely treatment decisions, and poses minimal risk when used for management decisions. A corresponding podcast is available below.
Baker M, et al. Practical Implementation of Remote Continuous Glucose Monitoring in Hospitalized Patients with Diabetes. Am J Health Syst Pharm. 2022;79(6):452-458.
Learn MoreManagement of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline
November 9, 2022Clinical Outcomes Article / Publication
A clinical practice guideline for inpatient hyperglycemia management from the Endocrine Society was published in The Journal of Clinical Endocrinology & Metabolism. The guideline focuses on hyperglycemia management in non-critically ill hospitalized patients and highlights the use of emerging diabetes technology, including real-time continuous glucose monitoring (RT-CGM), for glycemic management in the hospital. Based on available evidence, the guideline recommends use of RT-CGM with confirmatory point-of-care (POC) testing for insulin dosing decisions in adults with insulin-treated diabetes hospitalized for noncritical illness who are at high risk of hypoglycemia.
Korytkowski M, et al. Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2022;107(8):2101-2128.
Learn MoreNovember 7, 2022Clinical Outcomes Coverage and Benefit Design Article / PublicationLearn MoreNovember 4, 2022Population Health Webinar / Archive
Diana Isaacs, PharmD, and the Transformation of Diabetes through Time in Range
LEARN MOREAMGA Member Best Practices: Driving Population Health Outcomes with Connected Continuous Glucose Monitors
November 2, 2022Clinical Outcomes CGM Best Practices / Webinar / Archive
Health Equity and Diabetes Technology: A Study of Access to Continuous Glucose Monitors by Payer and Race Executive Summary
October 27, 2022CGM Technology and Digital Health Coverage and Benefit Design Population Health Article / PublicationLearn MoreOctober 12, 2022Economic Outcomes CGM Best Practices / Interview
Expert: Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner at Henry Ford Health System (HFHS)/Health Alliance Plan (HAP)
Summary: HFHS/HAP’s experience in moving continuous glucose monitoring (CGM) from the durable medical equipment (DME) benefit to pharmacy coverage, demonstrating substantial cost savings at the plan level.
Short on time? Click here for an abbreviated version of this video interview.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Continuous Glucose Monitoring–Guided Insulin Administration in Hospitalized Patients With Diabetes: A Randomized Clinical Trial
This randomized control trial (RCT) of 185 general medicine and surgery patients with Type 1 and Type 2 diabetes found real-time continuous glucose monitoring (RT-CGM) safe and effective for guiding insulin therapy in hospitalized patients treated with a basal-bolus insulin regimen compared with a point-of-care (POC) group with blinded CGM and POC-guided insulin adjustments. RT- CGM resulted in a similar improvement in glycemic control and a significant reduction of recurrent hypoglycemia among patients with one or more hypoglycemic events compared with POC group.
Spanakis, EK et al. Continuous Glucose Monitoring–Guided Insulin Administration in Hospitalized Patients with Diabetes: A Randomized Clinical Trial. Diabetes Care. Diabetes Care. 2022;45(10):2369-2375.
Learn MorePractical Implementation of Remote Continuous Glucose Monitoring in Hospitalized Patients with Diabetes
November 9, 2022Clinical Outcomes Article / Publication
This publication describes a retrospective analysis of an inpatient real-time continuous glucose monitoring (RT-CGM) program at a community hospital and the accuracy of the system. Authors concluded RT-CGM for inpatient diabetes monitoring is feasible, is a reliable comparator to POC (point-of-care) testing, prevents adverse patient outcomes through safe and timely treatment decisions, and poses minimal risk when used for management decisions. A corresponding podcast is available below.
Baker M, et al. Practical Implementation of Remote Continuous Glucose Monitoring in Hospitalized Patients with Diabetes. Am J Health Syst Pharm. 2022;79(6):452-458.
Learn MoreManagement of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline
November 9, 2022Clinical Outcomes Article / Publication
A clinical practice guideline for inpatient hyperglycemia management from the Endocrine Society was published in The Journal of Clinical Endocrinology & Metabolism. The guideline focuses on hyperglycemia management in non-critically ill hospitalized patients and highlights the use of emerging diabetes technology, including real-time continuous glucose monitoring (RT-CGM), for glycemic management in the hospital. Based on available evidence, the guideline recommends use of RT-CGM with confirmatory point-of-care (POC) testing for insulin dosing decisions in adults with insulin-treated diabetes hospitalized for noncritical illness who are at high risk of hypoglycemia.
Korytkowski M, et al. Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2022;107(8):2101-2128.
Learn MoreNovember 7, 2022Clinical Outcomes Coverage and Benefit Design Article / PublicationLearn MoreNovember 4, 2022Population Health Webinar / Archive
Diana Isaacs, PharmD, and the Transformation of Diabetes through Time in Range
LEARN MOREAMGA Member Best Practices: Driving Population Health Outcomes with Connected Continuous Glucose Monitors
November 2, 2022Clinical Outcomes CGM Best Practices / Webinar / Archive
Health Equity and Diabetes Technology: A Study of Access to Continuous Glucose Monitors by Payer and Race Executive Summary
October 27, 2022CGM Technology and Digital Health Coverage and Benefit Design Population Health Article / PublicationLearn MoreOctober 12, 2022Economic Outcomes CGM Best Practices / Interview
Expert: Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner at Henry Ford Health System (HFHS)/Health Alliance Plan (HAP)
Summary: HFHS/HAP’s experience in moving continuous glucose monitoring (CGM) from the durable medical equipment (DME) benefit to pharmacy coverage, demonstrating substantial cost savings at the plan level.
Short on time? Click here for an abbreviated version of this video interview.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Practical Implementation of Remote Continuous Glucose Monitoring in Hospitalized Patients with Diabetes
This publication describes a retrospective analysis of an inpatient real-time continuous glucose monitoring (RT-CGM) program at a community hospital and the accuracy of the system. Authors concluded RT-CGM for inpatient diabetes monitoring is feasible, is a reliable comparator to POC (point-of-care) testing, prevents adverse patient outcomes through safe and timely treatment decisions, and poses minimal risk when used for management decisions. A corresponding podcast is available below.
Baker M, et al. Practical Implementation of Remote Continuous Glucose Monitoring in Hospitalized Patients with Diabetes. Am J Health Syst Pharm. 2022;79(6):452-458.
Learn MoreManagement of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline
November 9, 2022Clinical Outcomes Article / Publication
A clinical practice guideline for inpatient hyperglycemia management from the Endocrine Society was published in The Journal of Clinical Endocrinology & Metabolism. The guideline focuses on hyperglycemia management in non-critically ill hospitalized patients and highlights the use of emerging diabetes technology, including real-time continuous glucose monitoring (RT-CGM), for glycemic management in the hospital. Based on available evidence, the guideline recommends use of RT-CGM with confirmatory point-of-care (POC) testing for insulin dosing decisions in adults with insulin-treated diabetes hospitalized for noncritical illness who are at high risk of hypoglycemia.
Korytkowski M, et al. Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2022;107(8):2101-2128.
Learn MoreNovember 7, 2022Clinical Outcomes Coverage and Benefit Design Article / PublicationLearn MoreNovember 4, 2022Population Health Webinar / Archive
Diana Isaacs, PharmD, and the Transformation of Diabetes through Time in Range
LEARN MOREAMGA Member Best Practices: Driving Population Health Outcomes with Connected Continuous Glucose Monitors
November 2, 2022Clinical Outcomes CGM Best Practices / Webinar / Archive
Health Equity and Diabetes Technology: A Study of Access to Continuous Glucose Monitors by Payer and Race Executive Summary
October 27, 2022CGM Technology and Digital Health Coverage and Benefit Design Population Health Article / PublicationLearn MoreOctober 12, 2022Economic Outcomes CGM Best Practices / Interview
Expert: Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner at Henry Ford Health System (HFHS)/Health Alliance Plan (HAP)
Summary: HFHS/HAP’s experience in moving continuous glucose monitoring (CGM) from the durable medical equipment (DME) benefit to pharmacy coverage, demonstrating substantial cost savings at the plan level.
Short on time? Click here for an abbreviated version of this video interview.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline
A clinical practice guideline for inpatient hyperglycemia management from the Endocrine Society was published in The Journal of Clinical Endocrinology & Metabolism. The guideline focuses on hyperglycemia management in non-critically ill hospitalized patients and highlights the use of emerging diabetes technology, including real-time continuous glucose monitoring (RT-CGM), for glycemic management in the hospital. Based on available evidence, the guideline recommends use of RT-CGM with confirmatory point-of-care (POC) testing for insulin dosing decisions in adults with insulin-treated diabetes hospitalized for noncritical illness who are at high risk of hypoglycemia.
Korytkowski M, et al. Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2022;107(8):2101-2128.
Learn MoreNovember 7, 2022Clinical Outcomes Coverage and Benefit Design Article / PublicationLearn MoreNovember 4, 2022Population Health Webinar / Archive
Diana Isaacs, PharmD, and the Transformation of Diabetes through Time in Range
LEARN MOREAMGA Member Best Practices: Driving Population Health Outcomes with Connected Continuous Glucose Monitors
November 2, 2022Clinical Outcomes CGM Best Practices / Webinar / Archive
Health Equity and Diabetes Technology: A Study of Access to Continuous Glucose Monitors by Payer and Race Executive Summary
October 27, 2022CGM Technology and Digital Health Coverage and Benefit Design Population Health Article / PublicationLearn MoreOctober 12, 2022Economic Outcomes CGM Best Practices / Interview
Expert: Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner at Henry Ford Health System (HFHS)/Health Alliance Plan (HAP)
Summary: HFHS/HAP’s experience in moving continuous glucose monitoring (CGM) from the durable medical equipment (DME) benefit to pharmacy coverage, demonstrating substantial cost savings at the plan level.
Short on time? Click here for an abbreviated version of this video interview.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
November 4, 2022Population Health Webinar / Archive
Diana Isaacs, PharmD, and the Transformation of Diabetes through Time in Range
LEARN MOREAMGA Member Best Practices: Driving Population Health Outcomes with Connected Continuous Glucose Monitors
November 2, 2022Clinical Outcomes CGM Best Practices / Webinar / Archive
Health Equity and Diabetes Technology: A Study of Access to Continuous Glucose Monitors by Payer and Race Executive Summary
October 27, 2022CGM Technology and Digital Health Coverage and Benefit Design Population Health Article / PublicationLearn MoreOctober 12, 2022Economic Outcomes CGM Best Practices / Interview
Expert: Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner at Henry Ford Health System (HFHS)/Health Alliance Plan (HAP)
Summary: HFHS/HAP’s experience in moving continuous glucose monitoring (CGM) from the durable medical equipment (DME) benefit to pharmacy coverage, demonstrating substantial cost savings at the plan level.
Short on time? Click here for an abbreviated version of this video interview.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Diana Isaacs, PharmD, and the Transformation of Diabetes through Time in Range
AMGA Member Best Practices: Driving Population Health Outcomes with Connected Continuous Glucose Monitors
November 2, 2022Clinical Outcomes CGM Best Practices / Webinar / Archive
Health Equity and Diabetes Technology: A Study of Access to Continuous Glucose Monitors by Payer and Race Executive Summary
October 27, 2022CGM Technology and Digital Health Coverage and Benefit Design Population Health Article / PublicationLearn MoreOctober 12, 2022Economic Outcomes CGM Best Practices / Interview
Expert: Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner at Henry Ford Health System (HFHS)/Health Alliance Plan (HAP)
Summary: HFHS/HAP’s experience in moving continuous glucose monitoring (CGM) from the durable medical equipment (DME) benefit to pharmacy coverage, demonstrating substantial cost savings at the plan level.
Short on time? Click here for an abbreviated version of this video interview.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
AMGA Member Best Practices: Driving Population Health Outcomes with Connected Continuous Glucose Monitors
Health Equity and Diabetes Technology: A Study of Access to Continuous Glucose Monitors by Payer and Race Executive Summary
October 27, 2022CGM Technology and Digital Health Coverage and Benefit Design Population Health Article / PublicationLearn MoreOctober 12, 2022Economic Outcomes CGM Best Practices / Interview
Expert: Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner at Henry Ford Health System (HFHS)/Health Alliance Plan (HAP)
Summary: HFHS/HAP’s experience in moving continuous glucose monitoring (CGM) from the durable medical equipment (DME) benefit to pharmacy coverage, demonstrating substantial cost savings at the plan level.
Short on time? Click here for an abbreviated version of this video interview.
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Health Equity and Diabetes Technology: A Study of Access to Continuous Glucose Monitors by Payer and Race Executive Summary
October 12, 2022Economic Outcomes CGM Best Practices / Interview
Expert: Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner at Henry Ford Health System (HFHS)/Health Alliance Plan (HAP)
Summary: HFHS/HAP’s experience in moving continuous glucose monitoring (CGM) from the durable medical equipment (DME) benefit to pharmacy coverage, demonstrating substantial cost savings at the plan level.
Short on time? Click here for an abbreviated version of this video interview.
Expert: Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner at Henry Ford Health System (HFHS)/Health Alliance Plan (HAP)
Summary: HFHS/HAP’s experience in moving continuous glucose monitoring (CGM) from the durable medical equipment (DME) benefit to pharmacy coverage, demonstrating substantial cost savings at the plan level.
Short on time? Click here for an abbreviated version of this video interview.